Ambra Pozzi

(iStock image)
March 25, 2024

VUMC team finds potential treatment for kidney fibrosis

By Bill Snyder
Corina Borza, PhD, left, Ambra Pozzi, PhD, and colleagues are studying a certain cell surface receptor’s role in the process that leads to kidney failure.
February 2, 2022

VUMC study raises hope for improving treatment of kidney disease

Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure.

By Bill Snyder
January 20, 2022

Pozzi elected president of Society for Matrix Biology

Vanderbilt’s Ambra Pozzi, PhD, has been elected president of the American Society for Matrix Biology (ASMB), a scientific organization that promotes research on the extracellular matrix with the aim of improving human health.

By Bill Snyder
Insulin in vials
November 11, 2021

New way to bEET insulin resistance

Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

By Bill Snyder
July 30, 2020

Protein study may be key to treating fibrotic diseases

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.

By Bill Snyder
August 8, 2019

New window on fibrosis

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

By Bill Snyder
September 28, 2017

Major grant to enhance kidney disease research

Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease.
By Doug Campbell
May 11, 2017

EETs contribute to insulin sensitivity

Interventions that increase circulating levels of compounds called EETs may improve insulin sensitivity and treat hypertension.
By Leigh MacMillan
January 19, 2017

Surprising finding by VU team sheds light on fibrotic disease

Integrins are membrane proteins made up of combinations of different “alpha” and “beta” subunits that enable cells throughout the body to interact with their surroundings.
By Bill Snyder
July 10, 2014

Molecular ‘chat’ holds kidney fibrosis clues

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process.
By Leigh MacMillan
May 29, 2014

New center dedicated to kidney disease

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.
By Kathy Whitney
February 7, 2014

New direction for treating lung cancer

Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.
By Leigh MacMillan